KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $0.42.

  • Teva Pharmaceutical Industries' EPS (Basic) rose 32105.26% to $0.42 in Q4 2025 from the same period last year, while for Dec 2025 it was $1.24, marking a year-over-year increase of 18551.72%. This contributed to the annual value of $1.23 for FY2025, which is 18482.76% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' EPS (Basic) stood at $0.42, which was up 32105.26% from $0.38 recorded in Q3 2025.
  • Teva Pharmaceutical Industries' 5-year EPS (Basic) high stood at $0.42 for Q4 2025, and its period low was -$1.92 during Q4 2022.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.04 (2024), whereas its average is -$0.21.
  • Its EPS (Basic) has fluctuated over the past 5 years, first plummeted by 132857.14% in 2022, then skyrocketed by 32105.26% in 2025.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' EPS (Basic) stood at -$1.01 in 2021, then crashed by 89.14% to -$1.92 in 2022, then surged by 121.39% to $0.41 in 2023, then plummeted by 146.34% to -$0.19 in 2024, then surged by 321.05% to $0.42 in 2025.
  • Its last three reported values are $0.42 in Q4 2025, $0.38 for Q3 2025, and $0.25 during Q2 2025.